Osiris Therapeutics designated as Orphan Drug title holder by EMA Osiris Therapeutics announced that the European Medicines Agency, or EMA, has designated Osiris as the Orphan Drug title holder for Prochymal. The EU Commission adopted the decision to transfer the designation of Prochymal as an orphan medicinal product under Regulation, or EC, No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products.
News For OSIR From The Last 14 Days
Check below for free stories on OSIR the last two weeks.
Subscribe for More Information